References
- Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–592.
- Buemi M, Lacquaniti A, Bolignano D, et al. Dialysis and the elderly: An underestimated problem. Kidney Blood Press Res. 2008;31:330–336.
- Lacquaniti A, Bolignano D, Donato V, et al. Obestatin: A new element for mineral metabolism and inflammation in patients on hemodialysis. Kidney Blood Press Res. 2011;34:104–110.
- Lacquaniti A, Bolignano D, Campo S, et al. Malnutrition in the elderly patient on dialysis. Ren Fail. 2009;31:239–245.
- Van Bezooijen RL, Ten Dijke P, Papapoulos SE, Löwik CW. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005;16:319–327.
- Pelletier S, Confavreux CB, Haesebaert J, et al. Serum sclerostin: The missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos Int. 2015;26:2165–2174.
- Zhu D, Mackenzie NC, Millan JL, Farquharson C, Mac Rae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. Plos One. 2011;6:e19595.
- Kanbay M, Siriopol D, Saglam M, et al. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab. 2014;99:E1854–E1861.
- Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–832.
- Bielesz BO, Hempfing T, Kieweg H, Marculescu R, Haas M, Cejka D. Sclerostin declines during hemodialysis and appears in dialysate. Blood Purif. 2014;38:30–36.
- Drüeke TB, Lafage-Proust MH. Sclerostin: Just one more player in renal bone disease? Clin J Am Soc Nephrol. 2011;6:700–703.
- Veverka V, Henry AJ, Slocombe PM, et al. Characterization of the structural features and interactions of sclerostin: Molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem. 2009;284:10890.
- Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: Key roles for calcium and phosphate. Circ Res. 2011;109:697–711.
- Claes KJ, Viaene L, Heye S, et al. Sclerostin: Another vascular calcification inhibitor? J Clin Endocrinol Metab. 2013;98:3221–3228.
- Qureshi AR, Olauson H, Witasp A, et al. Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int. 2015;88:1356–1364.
- Desjardins L, Liabeuf S, Oliveira RB, et al. Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrol Ther. 2014;10:463–470.
- Yang CY, Chang ZF, Chau YP, et al. Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol Dial Transplant. 2015;30:1356–1363.